GeoVax to Participate in the 4th Symposium on Infectious Diseases in the Immunocompromised Host
April 26 2023 - 9:00AM
via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a
biotechnology company developing vaccines and immunotherapies
against cancers and infectious diseases, today announced its
participation in and sponsor support of the 4th Symposium on
Infectious Diseases in the Immunocompromised Host, being held April
30 to May 2, 2023, in Seattle, Washington and hosted by the Fred
Hutchinson Cancer Center. Medical leadership representation from
GeoVax will attend the event and will meet and interact with the
symposium speakers and attendees.
The 4th Symposium on Infectious Diseases in the
Immunocompromised Host brings together leaders and trainees in
research and clinical care of infectious diseases in the
immunocompromised host. The program features outstanding,
internationally recognized experts in the field, representing more
than 20 institutions, who will speak on topics including infections
in solid organ transplant, hematopoietic cell transplant, and
oncology. The symposium will address COVID-19, fungal disease,
respiratory viruses, CMV, HHV-6, immunotherapy, the microbiome, and
antimicrobial stewardship.
David Dodd, GeoVax’s Chairman and CEO, commented, “We are proud
to participate in this important symposium which highlights the
critical need for innovative approaches to preventing and treating
infections in vulnerable populations. At GeoVax, we remain
committed to advancing novel vaccine technologies such as CM04S1,
our next-generation COVID-19 vaccine being studied in two Phase 2
trials, that can potentially help protect and improve the lives of
immunocompromised individuals, representing those who are most
susceptible to infectious diseases.”
About GeoVax
GeoVax Labs, Inc. is a clinical-stage biotechnology company
developing novel therapies and vaccines for cancers and many of the
world’s most threatening infectious diseases. The company’s lead
program in oncology is a novel oncolytic solid tumor gene-directed
therapy, Gedeptin®, presently in a multicenter Phase 1/2 clinical
trial for advanced head and neck cancers. GeoVax’s lead infectious
disease candidate is GEO-CM04S1, a next-generation COVID-19 vaccine
targeting high-risk immunocompromised patient populations.
Currently in two Phase 2 clinical trials, GEO-CM04S1 is being
evaluated as a COVID-19 vaccine for immunocompromised patients such
as those suffering from hematologic cancers and other patient
populations for whom the current authorized COVID-19 vaccines are
insufficient. In addition, GEO-CM04S1 is in a Phase 2 clinical
trial evaluating the vaccine as a more robust, durable COVID-19
booster among healthy patients who previously received the mRNA
vaccines. GeoVax has a leadership team who have driven significant
value creation across multiple life science companies over the past
several decades.
For additional information about GeoVax, visit our website:
www.geovax.com.
Investor Relations Contact:Rich CockrellCG
Capital404-736-3838govx@cg.capital
GeoVax Labs (NASDAQ:GOVXW)
Historical Stock Chart
From Jul 2024 to Aug 2024
GeoVax Labs (NASDAQ:GOVXW)
Historical Stock Chart
From Aug 2023 to Aug 2024